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ABSTRACT 
Time has come for drug discovery and development of small molecules therapeutics to integrate genomics early in the drug discovery 
process .Through few significant examples, the manuscript highlights the need to take on board genomics issue in the medicinal 
chemistry process. If medicinal chemistry does not evolve, the question of spending decades to develop new drugs will raise, since 
other omics therapies will provide efficient treatments, less expensive and safer. 
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INTRODUCTION
Since the first synthesis of urea by Wohler in 1828[1], during 
decades chemists have made creditable efforts of creativity to 
develop innovative synthetic methodologies, to offer more and 
more safe and efficacious drugs to prevent and cure human 
diseases and sometimes with the secret hope to find one day the 
long life elixir. Unceasingly like painters, or sculptors, they have 
always tried to improve, expand and adapt their art for the 
wellness of humanity. It was not an easy task. After long and 
expensive clinical trials under the control of pharmacologists and 
physicians, drugs which overcome with success these clinical 
trials, were prescribed to men community. In this context creative 
medicinal chemists were pride to be the key actors of that central 
science. Starting from fundamental natural building blocks like 
amino-acids, nucleic bases, natural fatty acids, chemist designers 
have built fantastic architectural molecular edifices which can be 
seen as true works of art. Remember the first synthesis of vitamin 
B12 by Woodward (Nobel prize 1972) which represented a real 
achievement [2] At that time ‘’molecular, cellular, genomic’’ 
biology were not as developed as to-day, these ‘’omic sciences’’ 
were in their infancy. For the chemist community it was still the 
blessed time to develop drugs to cure any of diseases which strike 
human being health on earth. Yesterday medicinal chemistry was 
mainly based on the knowledge of few fundamental concepts 
derived from: 
Enzymology:  the design of competitive, non- competitive, 
uncompetitive  or  irreversible  enzyme inhibitors led to the 
discovery of potent clinically used drugs such as Lipitor 
(Atorvastatin ) an HMG-CoA inhibitor used as anti-cholesterol 
drug [3]  
Receptors : the design of agonists, antagonists or  inverse agonists 
specifically binding to topographically well-characterized 
receptors,   has led the discovery of important drugs such as Plavix 
(Clopidogrel),  an antithrombotic drug which binds to the ADP 
receptor [4] 
Ion channels ligands: Potent drugs (ions, small molecules, toxins 
or venom) have emerged from the knowledge of the ion channel 
mechanisms. Norvasc (Amlodipine) [5], a potent anti 
-hypertensive drug, or Nexium (Esomeprazole)[6]. a proton pump 
inhibitor used as anti-ulcer drug, are significant examples. 
The full understanding of these concept allow to teach  medicinal 
chemistry into a rational and coherent didactic discipline and help 
rational drug design. To- day, understanding drug action at a 
molecular level, is not sufficient. It is time for medicinal chemists 
to consider drug design at cellular or organismic levels. 
Why reorient the development of medicinal chemistry 
paradigm? 
Pharma companies routinely spend hundreds of millions of dollars 
on developing drugs only to see more than 90 percent of them, fail 
in clinical trials or later. It becomes obvious to change the drug 
discovery approach. Only highly promising drugs at late stages of 
development should be checked out on humans in clinical trials. 
But economic and ethical reasons make that approach impossible 
in the early stages of drug. This is the reason why new drugs are 
tested on animal or on cultured cells. Unfortunately experiments 
on non- human models and their tissues are notoriously 
problematic, even if they have historically been the best available 
option. Animal’s physiologies don't always respond to drugs 
exactly as the human body would; moreover, not all human 
diseases have good animal models [7].  
The case of Alzheimer’s disease (AD) research is highly 
significant. In 2010, there were between 21 and 35 million people 
worldwide with AD  [8] .Unfortunately, to day, no efficacious 
drugs for the treatment of AD are available, but if they were, to 
whom would they be prescribed?  
-To patients in the early stages of the disease to circumvent further 
development? 
-To patients already at an advanced stage of the disease? 
These questions are difficult to answer .Once a patient has been 
clearly diagnosed with AD, the prospect of restoring their normal 
neuroplasticity through the use of drugs becomes uncertain for a 
majority of neurobiologists. Because of the great challenge and 
high risks associated with CNS drug discovery and development, 
several major pharmaceutical companies are exiting or 
depriorizing CNS drug search in response to investor pressure [9]. 
In front of this situation and in order to overcome those major 
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problems, research on AD therapy will progressively reorient 
towards immunotherapy (vaccine) or gene therapy [10]. It will 
become more likely that future medicine will turn more and more 
to biotechnologies, leaving medicinal chemistry by the wayside, 
consequently cellular therapy  and more specifically stem cells 
therapies will be used to treat or to prevent some specific diseases. 
Research is underway to develop various sources for stem cells( 
bone marrow transplant or umbelical cord blood ) which will 
constitute  stem cell treatments for neurodegenerative diseases, 
diabetes, heart disease. As an example ,regeneration of damaged 
tissue in the back of the eye ( retina stem cell therapy ) [11] is a 
significant sign that biotechnologies will represent the to-morrow 
therapies. 
Today both chemotherapy and genomic therapy are on the road. 
Chemotherapy is still dominating but genomic therapy is spirit to 
rapidly remake its delay. Probably for a while both ways to 
prevent and to cure men’s diseases will be used in an integrated 
manner  , but in the future, genomic knowledge rapidly 
progressing will become the central science to which human 
beings will resort to look after their health evils. Cancer and 
neurodegenerative diseases are excellent examples of how 
medicinal chemistry and biotechnology should cooperate to 
promote the best and most cost effective treatment for these 
diseases.  
Biotechnology and cancer 
Around 40 new anti-cancer drugs are in clinical development, and 
nearly a dozen of them are in phase III testing around the world 
,but in the same time U.S. Food and Drug Administration 
approved therapeutic cancer vaccines that treats malignancy by 
turning immunity against it .Ipilimumab (Yervoy), which 
accelerates antitumor immunity in patients with metastatic 
melanoma is a significant example [12] .BiovaxID, is a cancer 
vaccine in phase III which lengthens disease-free survival in 
patients with follicular lymphoma by an average of nearly 14 
months, with virtually no side effects [13]. .Scientists attribute this 
success to a better understanding of how tumors fight off the 
immune system. If progress continues, immunotherapy will 
increasingly be used to prevent tumor recurrence in patients who 
complete first-line treatments. Ideally these vaccines will attack 
any new cancer cells, while leaving normal cells alone. 
Unfortunately immunotherapies, which don’t  target tumors 
directly, have  first to turn on the immune system against cancer, 
which takes longer to work than actual drug chemotherapy 
treatments.  
Biotechnology and neurodegenerative diseases . 
 No efficient drugs against motor neurons diseases like Spinal 
Muscular Atrophy (SMA) and Amyotrophic Lateral Sclerosis 
(ALS) are actually available. Medicinal chemists from a small 
pharma are trying to find new small molecules able to tackle this 
rare disease .After 15 years of research and development, this 
small pharma reports recent promising results from clinical trials 
which let foresee the possible approval of first drug against, 
Survival Motor Neuron (SMN) protein which is the major cause of 
SMA [14] .At the same time in 2008 researchers from Harvard 
University and Columbia University have succeeded to generate 
iPS (induced Pluripotent Stem) cells from a 82 years old woman 
diagnosed with a familial form of ALS. Those iPS cells , have 
been successfully directed to differentiate into motor neurons, 
which are destroyed in ALS[15] .From these results it could be 
anticipated that cellular therapy could be rapidly applied for the 
treatment for this rare motor neuron diseases . 
From these examples, one can ask the question if it is still worthy 
to spend decades to develop new drugs if biotechnology processes 
(cellular, gene or immune therapy) can provide efficient 
treatments, less expensive and more safer than traditional drug 
therapy? 
Chemical genomics as a starting point for drug discovery  
When Watson and Crick discovered 60 years ago that our bodies 
were coded in genes, it was an accomplishment with deep and 
lasting impact but now science has connected genes and disease. 
Hard wired in our chromosomes are instructions to make drugs 
work, fail, or produce side effects. The human genetic code 
appears to be the key to health and to disease. From families where 
everyone lives into their 90s, genes which make resistant to illness 
were progressively identified while in parallel through siblings 
with the same illness, genes which increase the risk of specific 
disease were pinpointed. As a consequence gene therapy and 
cellular therapy appear the most appropriate therapies to diagnose, 
to treat and hopefully to cure human diseases .At the same time, 
patient personalized chemotherapy could emerge if medicinal 
chemists integrate early in their drug discovery approach, 
genomic elements through the use of gene or protein microarrays 
techniques. Indeed DNA microarrays have proven very useful in 
elucidating the functions of the drug biological targets [16]. By 
comparing the differences between the profile before and after 
drug treatment, genes whose expression are modulated by the 
chemical ligand, can be identified. Those information can often 
reveal specific transcription factors and other regulators for each 
pool of genes, while genetic study interactions can unravel the 
genetic basis for drug sensitivity. Some cancer cells are more 
resistant or prone to certain anticancer drugs; therefore drug 
sensitivity profiles for different type of cancer, will be developed 
starting from genes, which expression involved specific biological 
pathways in which the drug interfere. Hence for a patient suffering 
of a given pathology knowing its own genomic profile, and 
knowing the ability of some drugs to deregulate genes, selected 
drugs will be prescribed to him, alone or in combination with 
immunotherapy treatment. If genomic chemistry is incorporated 
early in drug discovery process, the next futuristic reorientation 
for medicinal chemistry will be how to find ways to bridge living 
(cellular and gene therapy) and nonliving  (  classic chemical 
drugs) systems?  
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